Skip to content
Screener

Eli Lilly LLY EV / EBITDA

EV / EBITDA at other companies

Pfizer logo
PfizerPFE
12.9×
Amgen logo
AmgenAMGN
15.9×-1.3×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×
Mannkind logo
MannkindMNKD
18.8×-9.0×
McKesson logo
McKessonMCK
16.1×-2.6×
Exelixis logo
ExelixisEXEL
11.6×-1.3×

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.02T+48.4%
Enterprise value$1.06T+46.2%
P/E40.5×-9.5×
P/S14.2×+1.2×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Calculated from Eli Lilly’s reported figures.

Based on the most recent quarter.

The source filing: Eli Lilly’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 30, 2026, 11:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000059478-26-000045

FAQ

What is Eli Lilly's EV / EBITDA?
Eli Lilly (LLY) reported EV / EBITDA of 25.9× in Q1 2026.
How has Eli Lilly's EV / EBITDA changed year-over-year?
Eli Lilly's EV / EBITDA decreased by 48.5% year-over-year, from 50.4× to 25.9×.
What is the long-term trend for Eli Lilly's EV / EBITDA?
Over 5 years (2020 to 2025), Eli Lilly's EV / EBITDA has grown at a 11.9% compound annual growth rate (CAGR), from 20.5× to 36×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Eli Lilly's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude